Q1 Earnings Estimate for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Avadel Pharmaceuticals in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings of ($0.14) per share for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at $0.00 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $1.65 EPS.

Several other brokerages also recently issued reports on AVDL. Deutsche Bank Aktiengesellschaft began coverage on shares of Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target on the stock. Piper Sandler lowered their target price on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a report on Wednesday, April 9th. UBS Group reduced their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Avadel Pharmaceuticals has an average rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Trading Down 1.5 %

Shares of AVDL opened at $8.03 on Wednesday. The firm has a market capitalization of $775.93 million, a P/E ratio of -10.16 and a beta of 1.52. The firm’s 50-day moving average is $8.01 and its two-hundred day moving average is $10.03. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $19.09.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Wealth Effects LLC boosted its stake in Avadel Pharmaceuticals by 4.9% during the fourth quarter. Wealth Effects LLC now owns 2,344,130 shares of the company’s stock valued at $24,637,000 after buying an additional 110,359 shares in the last quarter. State Street Corp raised its holdings in Avadel Pharmaceuticals by 42.5% during the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company’s stock worth $21,290,000 after buying an additional 483,787 shares during the period. SG Americas Securities LLC lifted its stake in Avadel Pharmaceuticals by 274.6% during the fourth quarter. SG Americas Securities LLC now owns 46,767 shares of the company’s stock valued at $492,000 after buying an additional 34,281 shares in the last quarter. Barclays PLC boosted its holdings in shares of Avadel Pharmaceuticals by 45.8% in the third quarter. Barclays PLC now owns 392,691 shares of the company’s stock worth $5,150,000 after buying an additional 123,430 shares during the period. Finally, Lord Abbett & CO. LLC raised its holdings in shares of Avadel Pharmaceuticals by 23.9% during the third quarter. Lord Abbett & CO. LLC now owns 489,073 shares of the company’s stock valued at $6,414,000 after acquiring an additional 94,239 shares during the period. Institutional investors and hedge funds own 69.19% of the company’s stock.

Insider Activity

In other Avadel Pharmaceuticals news, Director Linda Palczuk bought 5,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were purchased at an average cost of $7.93 per share, for a total transaction of $39,650.00. Following the transaction, the director now directly owns 67,900 shares in the company, valued at $538,447. The trade was a 7.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.